Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

Journal of Clinical Oncology

Volumn 18, Issue 23, 2000, Pages 3964-3973

  Marshall, John L ^a   Hoyer, Robert J ^a   Toomey, Mary Ann ^a   Faraguna, Kristen ^a   Chang, Ping ^a   Richmond, Ellen ^a   Pedicano, James E ^a   Gehan, Edmund ^a   Peck, Ronald A ^a   Arlen, Philip ^a   Tsang, Kwong Y ^a   Schlom, Jeffrey ^a  

^a UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIPOX VACCINE; CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ADULT; ADVANCED CANCER; AGED; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FOWLPOX VIRUS; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROLYMPHOCYTE; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 0034551730     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.23.3964     Document Type: Article

References (30)

1. Carcinoembryonic antigens and related glycoproteins: Molecular aspects and specificity
2. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal human adult tissues
3. Carcinoembryonic antigen in breast cancer patients: Serum levels and disease progress
4. Carcinoembryonic antigen in patients with carcinoma of the lung
5. Colorectal carcinoma and carcinoembryonic antigen (CEA)
6. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule
7. Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: Lack of correlation
8. Anti-tumor activity and immune responses induced by a recombinant vaccinia-carcinoembryonic antigen (CEA) vaccine
9. Recombinant poxvirus vaccines
10. Carcinoembryonic antigen (CEA) peptides and vaccines for carcinoma
11. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from cancer patients immunized with recombinant vaccinia-CEA vaccine
12. Immunogenicity and safety of a recombinant vaccinia virus expressing the carcinoembryonic antigen (CEA)-vaccine in a non-human primate
13. Results of phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer
14. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen
15. Specific cytolytic T-cell responses to human carcinoembryonic antigen from patients immunized with recombinant canarypox (ALVAC)-CEA vaccine
16. Identification of an Enhancer Agonist CTL Peptide from Human Carcinoembryonic Antigen
17. Agonist peptide from a cytotoxic T lymphocyte epitope of human carcinoembryonic antigen stimulates production of Tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate antigen
18. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to enhance T-cell immunity and antitumor responses
19. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
20. Improved immunotherapy of a recombinant CEA vaccine when given in combination with interleukin- 2
21. Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen presenting cells in regional lymph nodes
22. Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines
23. Pharmacological administration of granulocyte/macrophage colony stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen
24. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA, class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients
25. Identification of HLA-A2402 restricted and carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte
26. The use of Epstein Barr virus transformed B lymphocyte cell lines in a peptide-reconstitution assay: Identification of CEA-related HLA-A*0301-restricted potential cytotoxic T lymphocyte epitopes
27. A triad of costimulatory molecules synergize to amplify T cell activation
28. Lymphokine production by human T cells in disease states
29. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression
30. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: Time to consider the TH1/TH2 paradigm